Naratriptan Stada

Naratriptan, the active ingredient in Naratriptan Stada, is a Triptan presented as a tablet for oral use. It treats acute migraine attacks in adults, providing relief from headache pain and associated symptoms.

GNH USA supplies Naratriptan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan is a Triptan indicated for the acute treatment of migraine attacks.

Migraine with aura: reduces headache intensity and associated neurological symptoms. Migraine without aura: provides rapid relief of pain, nausea and photophobia. Menstrual migraine: helps alleviate headache and related discomfort during menstrual cycles.

Naratriptan may cause a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness. - Fatigue: feeling of tiredness. - Dry mouth: reduced salivation. - Chest discomfort: mild pressure in the chest. - Tingling sensation: paresthesia in extremities.

Serious or Rare Side Effects: - Coronary vasospasm: constriction of heart arteries that can cause chest pain. - Myocardial infarction: rare heart attack event. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic drugs. - Severe hypertension: sudden high blood pressure. - Allergic reactions: rash, swelling, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythm.

When prescribing Naratriptan, clinicians should consider several safety measures to minimize risk.

Assess cardiovascular risk: evaluate history of coronary artery disease before use. Avoid in uncontrolled hypertension: monitor blood pressure and limit use. Caution with serotonergic agents: assess potential for serotonin syndrome. Limit dosing frequency: do not exceed one dose per migraine attack, maximum two doses per 24 hours. Discontinue if severe adverse reactions occur: seek immediate medical attention. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Naratriptan can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Ergotamine or ergot derivatives: additive vasoconstriction may cause coronary events. - Other triptans: combined use can lead to excessive vasoconstriction.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): monitor for serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase naratriptan plasma levels. - Antihypertensive agents: possible additive blood pressure lowering effect.